HilleVax (NASDAQ:HLVX) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reiterated their neutral rating on shares of HilleVax (NASDAQ:HLVX) in a research note published on Monday morning, Benzinga reports. The firm currently has a $2.00 target price on the stock. HC Wainwright also issued estimates for HilleVax’s Q3 2024 earnings at ($0.37) EPS, Q4 2024 earnings at ($0.20) EPS, FY2024 earnings at ($2.35) EPS, FY2025 earnings at ($1.35) EPS, FY2026 earnings at ($1.28) EPS, FY2027 earnings at ($1.22) EPS and FY2028 earnings at ($0.61) EPS.

Other equities analysts also recently issued research reports about the company. SVB Leerink downgraded HilleVax from an outperform rating to a market perform rating and dropped their price objective for the company from $28.00 to $2.00 in a research note on Tuesday, July 9th. Stifel Nicolaus downgraded shares of HilleVax from a buy rating to a hold rating and lowered their price target for the stock from $34.00 to $3.00 in a research note on Tuesday, July 9th. JPMorgan Chase & Co. reiterated a neutral rating and issued a $5.00 price target (down previously from $24.00) on shares of HilleVax in a report on Monday, July 8th. Guggenheim downgraded HilleVax from a buy rating to a neutral rating in a report on Monday, July 8th. Finally, Leerink Partnrs cut shares of HilleVax from a strong-buy rating to a hold rating in a research report on Tuesday, July 9th. Six equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of Hold and a consensus target price of $9.20.

HilleVax Stock Performance

NASDAQ HLVX opened at $1.76 on Monday. HilleVax has a 52-week low of $1.55 and a 52-week high of $20.22. The stock has a market cap of $87.51 million, a PE ratio of -0.55 and a beta of 0.80. The firm has a 50-day moving average of $6.85 and a 200-day moving average of $12.15. The company has a debt-to-equity ratio of 0.11, a quick ratio of 10.92 and a current ratio of 10.92.

HilleVax (NASDAQ:HLVX) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.10). On average, sell-side analysts anticipate that HilleVax will post -2.58 EPS for the current year.

Insider Activity

In related news, Director Aditya Kohli sold 6,000 shares of the business’s stock in a transaction dated Monday, May 20th. The shares were sold at an average price of $15.45, for a total value of $92,700.00. Following the sale, the director now directly owns 776,878 shares in the company, valued at approximately $12,002,765.10. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 71.10% of the company’s stock.

Hedge Funds Weigh In On HilleVax

Several institutional investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC purchased a new position in shares of HilleVax during the 4th quarter worth approximately $139,000. abrdn plc bought a new stake in shares of HilleVax in the 4th quarter worth approximately $433,000. Swiss National Bank boosted its stake in HilleVax by 22.4% during the 4th quarter. Swiss National Bank now owns 38,200 shares of the company’s stock valued at $613,000 after purchasing an additional 7,000 shares during the period. Franklin Resources Inc. increased its position in shares of HilleVax by 4.1% during the 4th quarter. Franklin Resources Inc. now owns 1,846,396 shares of the company’s stock valued at $29,635,000 after purchasing an additional 71,938 shares during the period. Finally, Catalys Pacific LLC bought a new stake in shares of HilleVax in the 4th quarter worth approximately $21,009,000. Institutional investors and hedge funds own 86.42% of the company’s stock.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.